1Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantablecardioverter defibrillators to reduce patient morbidity [NCT00279279] by Wilkoff, Bruce L et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Trials
Open Access Study protocol
1Design of the Primary Prevention Parameters Evaluation 
(PREPARE) trial of implantablecardioverter defibrillators to reduce 
patient morbidity [NCT00279279]
Bruce L Wilkoff*†1, Richard Stern†2, Brian Williamson†3, Mark Wathen†4, 
Keith Holloman†5, Ann Fieberg†5 and Mark Brown†5
Address: 1The Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA, 2Doctors Medical Center, San 
Pablo, CA, USA, 3William Beaumont Hospital, Troy, MI, USA, 4Vanderbilt University, Nashville, TN, USA and 5Medtronic, Inc, Minneapolis, MN, 
USA
Email: Bruce L Wilkoff* - wilkofb@ccf.org; Richard Stern - richardsternmd@yahoo.com; Brian Williamson - bwilliamson@mhgpc.com; 
Mark Wathen - mark.wathen@vanderbilt.edu; Keith Holloman - keith.holloman@medtronic.com; 
Ann Fieberg - ann.m.fieberg@medtronic.com; Mark Brown - mark.l.brown@medtronic.com
* Corresponding author    †Equal contributors
Abstract
Background:  Implantable Cardioverter Defibrillator (ICD) therapy has been proven to be
beneficial and efficacious for the treatment of serious ventricular tachyarrhythmias in primary
prevention patients. However, primary prevention patients appear to have a lower incidence of
ventricular arrhythmias in comparison to secondary prevention patients and consequently likely
experience a higher proportion of detections due to supraventricular arrhythmias. Recent trials
have demonstrated that strategic and specific programming choices reduce the number of
inappropriate shocks and that anti-tachycardia pacing (ATP) is an effective alternative to shock
therapy for many sustained ventricular arrhythmias.
Methods: The Primary Prevention Parameters Evaluation (PREPARE) study is a multi-center
cohort study, evaluating the efficacy of a pre-specified strategic profile of VT/VF detection and
therapy settings in 700 primary prevention patients in an effort to safely reduce the number of
shock therapies delivered. The patients, both with and without cardiac resynchronization therapy,
are compared to a well-qualified set (n = 691) of historical controls derived from the MIRACLE
ICD and EMPIRIC trials. This manuscript describes the design of the PREPARE study. The study
results, to be presented separately, will characterize the efficacy of this programming set
(PREPARE) compared with physician-tailored programming (MIRACLE ICD and EMPIRIC).
Background
Implantable defibrillator therapy terminates ventricular
tachyarrhythmias and improves survival of patients in
multiple populations at risk of sudden cardiac death. [1-
3] Initially, ICD therapy was applied only to secondary
prevention patients: that is, those who had been resusci-
tated from a cardiac arrest or other sustained ventricular
tachyarrhythmias. The impact of other studies, such as
MADIT, MUSTT, MADIT II and SCD-HeFT, as well as the
CMS national coverage decision in January of 2005, is that
the large majority of patients currently receiving ICDs
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have primary prevention indications and no symptomatic
arrhythmias prior to ICD implantation. [4-8]
There are substantial differences in the clinical and
rhythm characteristics of patients with primary and sec-
ondary prevention indications for ICD therapy. However,
it is an important goal to minimize the morbidity of the
therapy for all ICD patients. Patients who receive multiple
shocks have difficulty adjusting to the ICD implantation,
due to increased anxiety and depression. [9,10] In addi-
tion, patients who have not had a significant life-threaten-
ing arrhythmic experience such as sudden cardiac death
may be less accepting of unnecessary shock therapies.
The EMPIRIC and Painfree Rx studies have shown that a
standardized set of VT/VF parameters extensively utilizing
SVT discriminators and anti-tachycardia pacing (ATP)
therapies can be effective in reducing patient shocks after
ICD implantation for a mixed population of primary and
secondary prevention patients. [11,12] It is the purpose of
the PREPARE trial to evaluate strategies specifically
designed to reduce shocks in a population of patients with
primary prevention ICD indications with and without car-
diac resynchronization indications and therapy.
Methods/Design
Hypothesis
The PREPARE study examines the hypothesis that a pre-
specified strategic profile of tachyarrhythmia detection
and therapy parameters is able to reduce the overall mor-
bidity of ICD therapy in patients with primary prevention
ICD indications with or without cardiac resynchroniza-
tion therapy.
Primary endpoint
Shock related morbidity is measured by the Morbidity
Index and expressed through the incidence density. How-
ever, the reduction of shocked episodes in primary pre-
vention patients via the use of a specific programming
profile is useful only if it does not result in an increase in
arrhythmogenic syncope and untreated sustained sympto-
matic VT/VF events. The Morbidity Index measures the
benefit of reducing the number of shocks while also
accounting for the possible side effects of 1) treating only
faster tachyarrhythmias (cycle-lengths greater than 330
ms) and 2) using a longer programmed delay before treat-
ing ventricular tachyarrhythmias with defibrillation.
Morbidity index
The components of the Morbidity Index are:
• Syncope (secondary to tachyarrhythmia or presumed
tachyarrhythmia)
• Untreated sustained symptomatic VT/VF events
• Episodes of spontaneous ventricular tachyarrhythmia
that result in device-delivered shock
• Episodes that result in an inappropriate device-delivered
shock.
Incidence Density (ID)
The Morbidity Index incidence density is calculated by
dividing the total number of Morbidity Index events by
the total number of years of follow-up. The primary end-
point is the difference in Morbidity Index incidence den-
sity between the study patients programmed to the
PREPARE settings and the control population pro-
grammed to physician-tailored programming.
Secondary endpoint
Morbidity Tachycardia Index
The key secondary endpoint is the difference in Morbidity
Tachycardia Index incidence density, which adds anti-
tachycardia pacing events to the Morbidity Index as a
reflection of all tachycardia events, between patients pro-
grammed to the PREPARE settings and the control popu-
lation.
Design
The PREPARE study is a prospective, single arm, multi-
center cohort study designed to evaluate the efficacy of a
pre-specified strategic profile of VT and VF detection and
therapy settings designed for ICD indicated patients with
no history of spontaneous sustained symptomatic VT or
VF. All study patients received a Medtronic Marquis family
ICD system with or without capacity for cardiac resyn-
chronization implanted between October 2003 and April
2005. Approximately 700 patients were enrolled in the
United States and the Netherlands and were programmed
to the PREPARE parameters and followed for endpoints
for 12 months after PREPARE programming.
For the purposes of this study, primary prevention
patients are defined as those patients indicated for ICD or
CRT + ICD implantation without a baseline history of
ventricular fibrillation, ventricular flutter, monomorphic
VT, polymorphic VT, or Torsades de Pointes. Patients may
have a history of cardiovascular syncope, since the PRE-
PARE findings are intended to be generalized to the pri-
mary prevention patient population seen in clinical
practice.
• Inclusion criteria required:
❍  Initial implantation for primary prevention ICD indica-
tions or
❍  Prior ICD implantation within 6 months without sub-
sequentTrials 2006, 7:18 http://www.trialsjournal.com/content/7/1/18
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spontaneous VT/VF episodes
• Patients were excluded for:
❍  History of spontaneous sustained symptomatic ven-
tricular arrhythmias,
❍  An electrophysiology test in the past, with sustained
inducible VT < 180 bpm,
❍  Any ICD implanted greater than 6 months prior to the
study,
❍  An ICD implanted within the previous 6 months, with
subsequent history of a spontaneous episode of VT or VF
appropriately treated with either ATP or shock.
❍  Heart transplant
❍  Mechanical right heart valve.
Control population
The control population consists of the prospectively col-
lected shock, tachycardia and event data combined from
two randomized clinical ICD trials; the MIRACLE ICD
Trial[13] and the EMPIRIC Trial. [11] Both of these trials
included both primary and secondary prevention
patients, but only the primary prevention patients were
included in the control population for the PREPARE anal-
ysis.
Originally, the control population included only the pri-
mary prevention patient data from the MIRACLE ICD
Trial. The MIRACLE ICD Trial was a multi-center rand-
omized trial of 978 CRT-ICD patients, designed to assess
the safety and effectiveness of biventricular CRT in pri-
mary and secondary prevention patients. However, in
contrast to the MIRACLE ICD Trial which enrolled only
patients receiving a cardiac resynchronization defibrilla-
tor (CRT+ICD), the PREPARE Study includes primary pre-
vention patients implanted with either an ICD or
CRT+ICD device. After an interim review of baseline char-
acteristics during the enrollment phase of the PREPARE
Trial, it became evident that 65% of the patient popula-
tion did not require a cardiac resynchronization device.
Therefore, the PREPARE Trial population was comprised
of patients with more favorable clinical characteristics
than the advanced heart failure patients enrolled in the
MIRACLE ICD Trial. This imbalance threatened to falsely
skew the results of the study, making it difficult to discern
whether the potential efficacy of the PREPARE parameters
would be the result of the recruitment of patients into the
PREPARE study with less severe disease.
To address the imbalanced baseline characteristics
between the PREPARE patients and the original control
population, the primary prevention patients from the
physician-tailored arm of the EMPIRIC study were com-
bined with MIRACLE ICD control patients to produce the
control population.
The EMPIRIC study was a multi-center randomized trial of
900 ICD patients, designed to compare standardized vs.
physician-tailored VT/VF programming in both primary
and secondary prevention patients. [11] The study was
recently completed, and its patient population is thought
to better reflect the higher ratio of ICD implant indica-
tions seen during enrollment into the PREPARE study
than the MIRACLE ICD Trial, reported in 2003. [13] Addi-
tionally, there were a large number of patients (276) ran-
domized in the EMPIRIC Trial to the physician-tailored
arm who met the PREPARE Trial definition of primary
prevention. These patients, along with the 415 primary
prevention patients from the MIRACLE ICD Trial, have
been combined, producing a total of 691 patients in the
historical control sample.
When compared with PREPARE patient baseline demo-
graphics, the patient characteristics of the combined phy-
sician-tailored arm are not clinically different. The
baseline clinical data for the study and control patients is
listed in Table 1. This table includes baseline demograph-
ics which were collected in PREPARE, MIRACLE ICD and
EMPIRIC. Demographics for MIRACLE ICD and EMPIRIC
are shown separately and in combination.
Programming
The strategies for reducing shock morbidity are to 1)
reduce over-treatment of self-terminating tachycardias, 2)
reduce the mis-identification of supraventricular arrhyth-
mias as ventricular arrhythmias, and 3) terminate ven-
tricular tachycardia with anti-tachycardia pacing as
frequently as possible. Since the patients enrolled in this
trial had never experienced a sustained ventricular
arrhythmia, the parameters were chosen to not treat: 1)
slow and presumably less symptomatic tachycardias, and
2) faster but self-terminating arrhythmias.
The exact tachycardia detection and therapy parameters
for the PREPARE study are listed in Table 2. In summary
two therapy zones are programmed, treating all rhythms
of cycle length less than 330 ms that meet the duration cri-
teria of 30 of 40 intervals. A single anti-tachycardia burst
is provided for tachycardias between 330 and 240 ms. If
the rhythm persists after ATP, a shock is provided.
Rhythms faster than 240 ms receive shocks as the first
therapy. A monitor zone is provided for tachycardia
between 360 and 330 ms. Many SVT discriminators are
programmed ON.Trials 2006, 7:18 http://www.trialsjournal.com/content/7/1/18
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The tachycardia detection and therapy parameters for the
MIRACLE ICD and EMPIRIC patients included in the con-
trol arm were chosen at the discretion of the investigators
and are referred to as "physician-tailored" parameters.
[14]
Data collection
These data are collected at the 6 and 12 month scheduled
visits and at unscheduled visits: cardiovascular adverse
events, cardiovascular medications, VT/VF and SVT epi-
sodes, and patient diary.
Adverse events of syncope, near-syncope, and dizziness
are collected between visits in a patient diary and evalu-
ated for arrhythmogenic syncope, i.e. syncope or near syn-
cope caused by a VT/VF or SVT episode, and symptomatic
VT/VF events i.e. VT/VF events that result in the symptoms
of near syncope or dizziness. All events in the PREPARE,
EMPIRIC and MIRACLE ICD Trials will be adjudicated by
the PREPARE Adverse Event Advisory Committee (AEAC)
to identify arrhythmogenic syncope, near-syncope, and
dizziness. The review includes the details surrounding
each adverse event and the available EGM data for epi-
sodes occurring within 24 hours of the event. For the his-
torical controls, where these adverse events were not as
rigorously collected, the event will be adjudicated when
the record indicated syncope, near-syncope, or dizziness
in the narrative of an adverse event.
The differences in data collection methods between stud-
ies are always of concern when utilizing a historical con-
trol. There are two particular sources of bias when
comparing the primary and key secondary endpoints in
the PREPARE study to the historical control data: 1)
adverse event collection and 2) incomplete adjudication
of VT/VF episodes.
Patients in the PREPARE study are required to record
adverse events of syncope, near-syncope, and dizziness in
a patient diary, in an effort to increase the probability of
collecting all occurrences of these events. By contrast, the
MIRACLE ICD study relied on patient recall at study visits,
and only system and procedure-related adverse events
were collected in the EMPIRIC study. These methods of
Table 1: Patient Demographics
PREPARE 
Patients
 (N = 700)
MIRACLE 
ICD Patients
(N = 415)
EMPIRIC 
Patients
(N = 276)
Combined Control (MIRACLE 
ICD and EMPIRIC) Patients
(N = 691)
Gender (N, %)
Male 555 (79.3%) 310 (74.7%) 222 (80.4%) 532 (77%)
Female 145 (20.7%) 105 (25.3%) 54 (19.6%) 159 (23%)
Age (years)
Mean ± Standard Deviation 67.4 ± 12.2 65.4 ± 11.5 65.6 ± 12 65.5 ± 11.7
Median 68.7 67.9 67.3 67.7
Minimum – Maximum 19.2 – 92.2 31 – 89 23.3 – 91.4 23.3 – 91.4
n (%) 700 (100%) 415 (100%) 276 (100%) 691 (100%)
Baseline Left Ventricular Ejection Fraction (%)
Mean ± Standard Deviation 27.7 ± 10.5 21 ± 6.8 30.3 ± 11 24.7 ± 9.8
Median 25 20 30 25
Minimum – Maximum 5 – 80 6 – 35 5 – 70 5 – 70
n (%) 691 (98.7%) 413 (99.5%) 273 (98.9%) 686 (99.3%)
Baseline New York Heart Association Classification 
(N, %)
Class I 117 (16.7%) 0 (0%) 36 (13%) 36 (5.2%)
Class II 297 (42.4%) 137 (33%) 102 (37%) 239 (34.6%)
Class III 268 (38.3%) 237 (57.1%) 36 (13%) 273 (39.5%)
Class IV 18 (2.6%) 41 (9.9%) 3 (1.1%) 44 (6.4%)
Not Collected* 0 (0%) 0 (0%) 99 (35.9%) 99 (14.3%)
Ischemic Cardiomyopathy 488 (69.7%) 238 (57.5%) 155 (56.2%) 393 (57.0%)
Myocardial Infarction (N, %) 421 (60.1%) 193 (46.6%) 192 (69.6%) 385 (55.8%)
N/A = not collected
*NYHA Class was only collected in the EMPIRIC Trial for patients with documented heart failureTrials 2006, 7:18 http://www.trialsjournal.com/content/7/1/18
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collection in the historical control group likely led to
underreporting of syncope related events, and therefore
decreased the probability of arrhythmogenic syncopal or
symptomatic VT/VF event discovery during these studies.
The expected consequence of this data limitation is that
higher rates of arrhythmogenic syncope and symptomatic
VT/VF events will be recorded in the PREPARE study.
Table 2: PREPARE Study VT/VF Programming
ICD Parameter Marquis/Maximo Family Programmed Value
INDUCTION
VF Detection ON
VFDI 330 ms
VF NID 30/40
VF RNID 9/12
DUAL CHAMBER
AF/AFl ON
Sinus Tachcardia ON
1:1 VT-ST Boundary 66%
Other 1:1 SVT OFF
SVT Limit 300
Stability OFF
SINGLE CHAMBER
Wavelet On, Match Threshold 70%
Stability 40
Onset 88%
ALL
VF Detection ON
VFDI 330 ms
VF NID 30/40
VF RNID 9/12
FVT Via VF
FVTDI 240 ms
VT Detection Monitor
VTDI 360 ms
VT NID 32
HR Timeout OFF
VF Rx 1–6 Status ON
VF Rx 1–6 Energy 30 or 35J maximum output of the ICD
VF Rx 1–4 Pathway AX->B
VF Rx 5–6 Pathway B->AX
VF Confirmation YES
FVT Rx 1–6 Status ON
FVT Rx 1 Type Burst
FVT Rx 1 Initial # Pulses 8
FVT Rx 1 R-S1 Interval 88%
FVT Rx 1 # sequence 1
FVT Rx 1 Smart Mode OFF
FVT Rx 2–6 Type CV
FVT Rx 2–6 Energy 30 to 35J maximum output of ICD
FVT Rx 2–5 Pathway AX->B
FVT Rx 6 Pathway B->AX
VT Rx 1–6 OFF
Other Diagnostic and Therapy parameters NominalsTrials 2006, 7:18 http://www.trialsjournal.com/content/7/1/18
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Not all episodes in the MIRACLE ICD study were origi-
nally adjudicated for the spontaneous/induced and true
VT/true SVT classifications. To avoid the bias that would
be incurred by dropping these episodes with missing
information, these will be reviewed and classified by an
internal Medtronic VT/VF scientist prior to the completion
of the PREPARE study.
Discussion
PREPARE programming strategies
1) Strategies to reduce shocks for VT/VF
❍  longer detection duration
VF initial beats to detect is set to 30 of 40 beats. At least
25% of ICD-detected VF is non-sustained VT/VF[15-17]
The extended detection duration may decrease unneces-
sary shocks by allowing for spontaneous termination of
non-sustained VT/VF that would otherwise be treated with
nominal settings of shorter detection duration.
❍  ATP for FVTs 330–240 ms
One sequence of ATP will be delivered for FVTs using the
FVT via VF zone. Approximately 81% of ICD-detected VF
(<320 ms) is monomorphic VT. Monomorphic VT can be
pace terminated 75% of the time with one sequence of
ATP. [12,15,18,19] It is anticipated that programming a
single sequence of ATP will reduce the use of shock ther-
apy in this patient population, and thereby improve the
patients' quality of life.
❍  maximum output for all VF therapy sequences and FVT sequence 
2–6
An initial high output shock may improve first shock suc-
cess and thus reduce the likelihood of multiple shock epi-
sodes. In addition, the slightly longer charge time may
allow more non-sustained VT/VF episodes to terminate
before the first shock.
2) Strategies to reduce shocks for SVTs
❍  tachycardia detection at 330 ms
A treated cut-off of 320 ms has been used in several large
primary prevention patient populations. [7,14,20] In the
latter two studies, investigators recommended a treatment
cut-off between 330 and 350 ms. Detection of only tach-
yarrhythmias faster than 330 ms should reduce the inap-
propriate detection of SVTs.
❍  VT monitor zone for slow VTs
One recent study showed that only about 5% of patients
with primary prevention indications experience mono-
morphic VT episodes slower than 360 ms. [21] Setting a
VT monitor zone between 360 and 330 ms is designed to
reduce the inappropriate detection of SVTs, but still allow
for identification of VT episodes below the therapy zone.
❍  longer detection duration
VF initial beats to detect is set to 30 of 40 beats which may
reduce detection of fast but nonsustained SVTs.
❍  PR logic (dual chamber) or Wavelet (single chamber)
SVT discriminators reduce detection of sustained SVTs of
300 ms (SVT Limit) or slower.
Statistical analysis
The primary endpoint is the difference in Morbidity Index
incidence density between the study patients pro-
grammed to the PREPARE settings and the control popu-
lation programmed to physician-tailored programming.
The PREPARE programming strategy will be considered
superior to the physician-tailored programming approach
if a statistically significant reduction in the incidence den-
sity is demonstrated in the PREPARE group when com-
pared to the historical control.
There were 347 shocked spontaneous VT/VF episodes, 4
events of arrhythmogenic syncope, and no episodes of
untreated symptomatic sustained VT/VF in the 691 con-
trol population patients followed for 503 years (ID =
0.70). Assuming that the PREPARE programming strategy
results in a 25% reduction in the number of shocked
spontaneous VT/VF episodes, the rates of arrhythmogenic
syncope and untreated symptomatic sustained VT/VF
events remain the same, and the same number of years of
follow-up, a total of 700 patients will provide at least 95%
power for the primary hypothesis, tested at the two-sided
significance level of 0.05. Both the Morbidity Index ID
and the secondary analysis of the Morbidity Tachycardia
Index ID will be tested using the comparison of incidence
rates test. [22]
Summary
The PREPARE study evaluates the ability of a pre-specified
programming strategy to reduce VT/VF episode-related
morbidity using a multi-center, prospective cohort design.
The primary prevention population of 700 defibrillator
patients with and without resynchronization therapy will
be compared to 691 historical control patients. The VT/VF
episode-related morbidity is assessed by a primary objec-
tive that indexes, for the number of years of follow-up, the
total number of shocked spontaneous VT/VF episodes,
untreated symptomatic sustained VT/VF episodes, and
arrhythmogenic syncopal events.
The use of ICD and CRT+ICD devices in the primary pre-
vention patient population has expanded dramatically
over the last five years. Optimal programming for these
patients has been investigated by other trials and under-
standing of these programming options continues to
evolve. The programming choices available in the current
devices enable additional specificity as it relates to theTrials 2006, 7:18 http://www.trialsjournal.com/content/7/1/18
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detection and treatment of ventricular arrhythmias. The
PREPARE study results will increase the understanding of
how to better develop programming strategies that posi-
tively impact primary prevention patients and their car-
egivers.
Abbreviations
AF/Afl: Atrial Fibrillation/Atrial Flutter
ATP: Anti-tachycardia Pacing
bpm: beats per minute
CRT: Cardiac Resynchronization Therapy
CRT + ICD: Cardiac Resynchronization Therapy with
Implantable Cardioverter Defibrillator
EGM: Electrogram
EMPIRIC Evaluation of EMPIRIC Programming to
Improve Patient Management
FVT: Fast Ventricular Tachycardia
FVTDI Fast Ventricular Tachycardia Detection Interval
HR Heart rate
ICD: Implantable Cardioverter Defibrillator
ID Incidence Density
MIRACLE ICD: Multicenter InSync ICD Randomized
Clinical Evaluation Trial
ms: milliseconds
PREPARE Primary Prevention Parameters Evaluation
Rx Therapy
ST/Sinus Tach: Sinus Tachycardia
SVT: Supraventricular Tachycardia
VF: Ventricular Fibrillation
VFDI: Ventricular Fibrillation Detection Interval
VF NID: Ventricular Fibrillation Number of Intervals to
Detect
VF RNID: Ventricular Fibrillation Number of Intervals to
Redetect
VT: Ventricular Tachycardia
VTDI: Ventricular Tachycardia Detection Interval
VT NID: Ventricular Tachycardia Number of Intervals to
Detect
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